• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢性结石患者的检查:适应证和诊断算法。

Metabolic Work-up of Patients with Urolithiasis: Indications and Diagnostic Algorithm.

机构信息

Division of Urology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Laboratoire des Lithiases, Service des Explorations Fonctionnelles, Hôpital Tenon, APHP, Paris, France.

出版信息

Eur Urol Focus. 2017 Feb;3(1):62-71. doi: 10.1016/j.euf.2017.03.014. Epub 2017 Apr 7.

DOI:10.1016/j.euf.2017.03.014
PMID:28720369
Abstract

CONTEXT

The incidence of urinary tract stone disease is increasing and the risk of recurrent stone formation is high. Appropriate therapeutic procedures with the aim of counteracting the progress of stone formation are highly desirable. Metabolic work-up is considered essential as a base for optimal design and follow-up of effective recurrence prevention.

OBJECTIVE

To scrutinize the current literature with regard to principles of metabolic work-up for this heterogeneous group of patients.

EVIDENCE ACQUISITION

Relevant articles in PubMed, guideline documents, consensus reports, and the Cochrane Library published during the past 20 yr were consulted.

EVIDENCE SYNTHESIS

Grades of recommendation were used according to the principles applied in the European Association of Urology and American Urological Association guidelines. Medical efforts to prevent recurrent stone formation should be part of the care of patients with urinary tract stone disease (grade of recommendation A). A careful medical history and imaging together with analysis of stone composition, blood, and urine provide the basis for appropriate measures, but the treatment has to be individualized (grade of recommendation D). Whenever possible, stone analysis should be carried out at least once for every patient or each time when a long time has elapsed between two stone episodes because the risk factors explaining stone formation may have changed (clinical principle). The medical history, including information on dietary and drinking habits as well as lifestyle, is necessary for appropriate advice (grade of recommendation C). The medical history, together with imaging and stone composition, is used to estimate the severity of the disease (clinical principle). Identification of specific medical conditions should be supported by blood and/or urine analysis (grade of recommendation B). Pharmacological agents associated with an increased risk of stone formation should be identified (grade of recommendation C). Patients who have formed noncalcium stones should always be given recurrence preventive treatment. Analysis of urine composition for these patients is optional, but might be of value in the follow-up to support decisions on appropriate dosage regimens (grade of recommendation C). For patients with idiopathic calcium stone disease information from 24-h urine samples should be used, although the number of samples to be taken is debated (grade of recommendation C). Information from 24-h urine analysis should be used for selective dietary and drinking advice as well as for selection of the most appropriate pharmacological agent (grade of recommendation B). The treatment effects on the risk of stone formation can be followed by estimates of supersaturation based on urine composition (grade of recommendation C).

CONCLUSIONS

It is clear that the metabolic work-up of patients with urinary tract stone disease should be individualized according to stone type and severity of the disease, and that the different therapeutic approaches are closely associated with the availability of therapeutic tools and motivation by the patient.

PATIENT SUMMARY

Effective prevention of recurrent stone formation is determined by several factors such as the current and previous stone episodes and surgical procedures, stone composition, medical history, dietary and drinking habits, lifestyle, and ongoing pharmacological therapy. Analysis of blood and urine is an important part of the metabolic evaluation, but how extensive the risk evaluation should be is determined by the type of stone and the severity of the disease.

摘要

背景

尿路结石病的发病率正在增加,结石复发的风险很高。人们非常希望采用适当的治疗方法来对抗结石形成的进展。代谢评估被认为是优化设计和随访有效预防复发的基础。

目的

检查针对这组异质患者的代谢评估的当前文献。

证据获取

在过去 20 年中,查阅了 PubMed 中的相关文章、指南文件、共识报告和 Cochrane 图书馆中发布的内容。

证据综合

根据欧洲泌尿外科学会和美国泌尿外科学会指南中应用的原则使用推荐等级。预防结石复发的医疗措施应成为尿路结石病患者护理的一部分(推荐等级 A)。仔细的病史和影像学检查以及结石成分、血液和尿液分析为采取适当措施提供了基础,但治疗必须个体化(推荐等级 D)。只要有可能,每个患者都应至少进行一次结石分析,或者在两次结石发作之间的时间间隔较长时进行分析,因为解释结石形成的危险因素可能已经发生了变化(临床原则)。病史包括饮食和饮水习惯以及生活方式方面的信息,这对于提供适当的建议是必要的(推荐等级 C)。病史结合影像学和结石成分用于估计疾病的严重程度(临床原则)。应通过血液和/或尿液分析支持特定医疗条件的识别(推荐等级 B)。应确定与结石形成风险增加相关的药物(推荐等级 C)。已形成非钙结石的患者应始终接受预防复发的治疗。对于这些患者,尿液成分分析是可选的,但可能有助于支持适当剂量方案的决策(推荐等级 C)。对于特发性钙结石病患者,应使用 24 小时尿液样本中的信息,尽管关于需要采集的样本数量存在争议(推荐等级 C)。24 小时尿液分析信息可用于选择性饮食和饮水建议以及选择最合适的药物(推荐等级 B)。基于尿液成分,可以通过估计过饱和度来监测治疗对结石形成风险的影响(推荐等级 C)。

结论

显然,根据结石类型和疾病严重程度,应个体化对尿路结石病患者进行代谢评估,并且不同的治疗方法与治疗工具的可用性以及患者的积极性密切相关。

患者总结

有效预防结石复发取决于多个因素,如当前和以前的结石发作和手术、结石成分、病史、饮食和饮水习惯、生活方式以及当前的药物治疗。血液和尿液分析是代谢评估的重要组成部分,但风险评估的范围取决于结石类型和疾病的严重程度。

相似文献

1
Metabolic Work-up of Patients with Urolithiasis: Indications and Diagnostic Algorithm.代谢性结石患者的检查:适应证和诊断算法。
Eur Urol Focus. 2017 Feb;3(1):62-71. doi: 10.1016/j.euf.2017.03.014. Epub 2017 Apr 7.
2
Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.代谢评估和预防尿路结石患者复发:EAU 指南。
Eur Urol. 2015 Apr;67(4):750-63. doi: 10.1016/j.eururo.2014.10.029. Epub 2014 Nov 20.
3
Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.肾结石形成的尿液危险因素的饮食治疗。CLU工作组综述
Arch Ital Urol Androl. 2015 Jul 7;87(2):105-20. doi: 10.4081/aiua.2015.2.105.
4
Management of urinary stones: state of the art and future perspectives by experts in stone disease.尿石症的管理:结石病专家的最新技术和未来展望。
Arch Ital Urol Androl. 2024 Jun 27;96(2):12703. doi: 10.4081/aiua.2024.12703.
5
[Functional evaluation in patients with kidney calculi].[肾结石患者的功能评估]
Srp Arh Celok Lek. 1998 Sep-Oct;126(9-10):394-8.
6
Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?代谢风险评估与结石病复发的预防:有意义吗?
Urolithiasis. 2016 Feb;44(1):91-100. doi: 10.1007/s00240-015-0840-y. Epub 2015 Nov 27.
7
[Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].[钙肾结石的病理生理学、诊断及保守治疗]
Ther Umsch. 2003 Feb;60(2):79-87. doi: 10.1024/0040-5930.60.2.79.
8
Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: An EAU Guidelines Update.代谢评估和预防尿路结石患者复发:EAU 指南更新。
Eur Urol. 2024 Oct;86(4):343-363. doi: 10.1016/j.eururo.2024.05.029. Epub 2024 Jul 27.
9
Urolithiasis: evaluation, dietary factors, and medical management: an update of the 2014 SIU-ICUD international consultation on stone disease.尿石症:评估、饮食因素和医学管理:2014 年 SIU-ICUD 国际结石病咨询会议的更新。
World J Urol. 2017 Sep;35(9):1331-1340. doi: 10.1007/s00345-017-2000-1. Epub 2017 Feb 3.
10
Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.饮食中补充钠治疗的低枸橼酸钙草酸钙结石患者尿结石危险因素的变化
J Urol. 2009 Mar;181(3):1140-4. doi: 10.1016/j.juro.2008.11.020. Epub 2009 Jan 18.

引用本文的文献

1
Metabolic Differences in 24-Hour Urine Parameters Between Calcium Oxalate Monohydrate and Dihydrate Kidney Stones: A Clinical Study.一水草酸钙和二水草酸钙肾结石患者24小时尿液参数的代谢差异:一项临床研究
Diagnostics (Basel). 2025 Apr 14;15(8):994. doi: 10.3390/diagnostics15080994.
2
Clinical, Diagnostic, and Metabolic Characteristics Associated with Nephrolithiasis in the Black Women's Health Study.黑人女性健康研究中与肾结石相关的临床、诊断和代谢特征
J Clin Med. 2024 Oct 7;13(19):5948. doi: 10.3390/jcm13195948.
3
Medical management of urolithiasis: Great efforts and limited progress.
尿石症的医学管理:付出巨大努力但进展有限。
Asian J Urol. 2024 Apr;11(2):149-155. doi: 10.1016/j.ajur.2023.05.001. Epub 2023 Jun 29.
4
Attitudes of urologists on metabolic evaluation for urolithiasis: outcomes of a global survey from 57 countries.泌尿科医生对尿石症代谢评估的态度:来自 57 个国家的全球调查结果。
Urolithiasis. 2022 Dec;50(6):711-720. doi: 10.1007/s00240-022-01362-x. Epub 2022 Sep 28.
5
UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.更新 - 加拿大泌尿外科学会指南:肾结石的评估与药物治疗
Can Urol Assoc J. 2022 Jun;16(6):175-188. doi: 10.5489/cuaj.7872.
6
Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis.24 小时尿渗透压作为充分水化的代表性指标,以及预测尿路结石患者复发的指标。
Int Urol Nephrol. 2019 Jul;51(7):1129-1135. doi: 10.1007/s11255-019-02108-2. Epub 2019 May 14.